公开(公告)号：US20230139516A1

公开(公告)日：2023-05-04

申请号：US17913760

申请日：2021-03-29

申请人： CEDARS-SINAI MEDICAL CENTER

发明人： Wei Yang

IPC分类号： A61K31/5025 ,  A61P35/02 ,  C12Q1/6886

摘要： Described herein are treatments and patient selection methods for cancers such as prostate cancer, breast cancer, liver cancer, bladder cancer, and melanoma. The treatment involves administering a RIPK2 inhibitor to a subject. The patient selection involves selecting a patient who has increased copy numbers or expression of both RIPK2 and MYC.

公开(公告)号：US20230138572A1

公开(公告)日：2023-05-04

申请号：US17822720

申请日：2022-08-26

申请人： GMDX CO PTY LTD

发明人： Robyn Alice Lindley

IPC分类号： C12Q1/6886 ,  A61N5/10

摘要： A method determines the likelihood that a subject has or will develop cancer. The method is based on identifying whether targeted somatic mutagenesis of a nucleic acid molecule by a mutagenic agent has occurred. The mutations are at one or more motifs recognized or targeted by the mutagenic agent such as AID, an APOBEC cytidine deaminase or aflatoxin, The nucleic acid molecule includes the whole exome. The cancer can be any of breast, prostate, liver, colon, pancreatic, skin, cervical, lymphoid, hematopoietic and ovarian cancer; and the biological sample comprises, respectively, breast, prostate, liver, colon, pancreatic, skin, cervical, lymphoid, hematopoietic or ovarian tissue or cells.

公开(公告)号：US20230135171A1

公开(公告)日：2023-05-04

申请号：US17788221

申请日：2020-12-23

申请人： Lexent Bio, Inc.

发明人： Alex ROBERTSON ,  Neil PETERMAN ,  Nicole LAMBERT ,  Haluk TEZCAN ,  Rohith SRIVAS ,  Peter GEORGE ,  Jason CLOSE

IPC分类号： C12Q1/6886 ,  G16B20/10 ,  G16B30/10 ,  C12Q1/6844

摘要： The present disclosure provides methods of assessing tumor status (e.g., progression, regression, recurrence, etc.) in a subject. In an aspect, a method for assessing tumor status (e.g., progression, regression, recurrence, etc.) of a subject may comprise: based on first and second WGS data of cfDNA molecules of a subject at different time points, determing (i) a first and second plurality of CNAs and (ii) a first and a second plurality of fragment lengths; processing the first and second plurality of CNAs to determine a CNA profile change; comparing the first and second plurality of fragment lengths to determine a fragment length profile change; determining a first or second tumor fraction of the subject at the first or second timepoint, based at least in part on the CNA profile change and the fragment length profile change; and detecting a tumor status of the subject based at least in part on the first or second tumor fraction.

公开(公告)号：US20230134045A1

公开(公告)日：2023-05-04

申请号：US17728224

申请日：2022-04-25

申请人： National Tsing Hua University ,  Taipei Medical University ,  CHANG GUNG MEMORIAL HOSPITAL, LINKOU

发明人： Wen-Ching Wang ,  Che-Chang Chang ,  Wen-Ling Kuo

IPC分类号： G01N33/574 ,  C12Q1/6886

摘要： The present disclosure provides a method for evaluating prognosis in a patient with breast cancer, including the following steps: (a) detecting the expression level of pyruvate kinase in a sample from the patient; (b) detecting the expression level of O-linked β-N-acetylglucosamine in the sample; and (c) evaluating a clinical treatment score post-5 years, wherein high expression levels of both the pyruvate kinase and the O-GlcNAc, and high score of the CTS5 indicate that the patient has a poor prognosis. The present disclosure also provides a kit for evaluating prognosis in a patient with breast cancer.

公开(公告)号：US20230133972A1

公开(公告)日：2023-05-04

申请号：US16500722

申请日：2018-04-04

申请人： UNIVERSITY OF MIAMI

发明人： Kerry L. Burnstein ,  Fiorella Magani

IPC分类号： G01N33/50 ,  C12Q1/6886

摘要： Described herein are materials and methods for the treatment of prostate cancer.

公开(公告)号：US20230132048A1

公开(公告)日：2023-04-27

申请号：US17611988

申请日：2020-04-28

申请人： INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

发明人： Hye Ryun KIM ,  In Suk LEE ,  Jae Won CHO

IPC分类号： C12Q1/6886

摘要： The present specification provides a method for providing information about a therapeutic response to anticancer immunotherapy, and a kit for providing information by using same, the method comprising: measuring DNA methylation of pDMRs in a biological sample isolated from a subject; and evaluating the therapeutic reaction to anticancer immunotherapy for the subject on the basis of the measured DNA methylation of pDMRs.

公开(公告)号：US20230130223A1

公开(公告)日：2023-04-27

申请号：US18083221

申请日：2022-12-16

申请人： The Johns Hopkins University

发明人： Jun Luo ,  Christian P. Pavlovich ,  William Brewster Isaacs ,  Jillian N. Eskra

IPC分类号： C12Q1/6886

摘要： Disclosed herein are methods for a RNA in situ hybridization assay workflow for the detection of target RNA within intact cells for the detection of prostate cancer cells in urine samples. The methods disclosed herein can identify a genetic susceptibility to prostate cancer in a subject and differentiate high risk from low risk prostate cancers. The methods disclosed herein can also include treatment and management strategies for prostate cancer and the prevention thereof.

公开(公告)号：US20230126920A1

公开(公告)日：2023-04-27

申请号：US17755721

申请日：2020-10-22

申请人： Beijing Institute of Genomics, Chinese Academy of Sciences (China National Center for Bioinformation ,  Peking University First Hospital

发明人： Weimin Ci ,  Zhengzheng Xu ,  Liqun Zhou

IPC分类号： C12Q1/6886 ,  G16B20/00 ,  G16B40/20

摘要： The present invention relates to a DNA classification method, comprising calculating the MHL value of a DNA methylation haplotype block and/or the DNA copy number variation data of a sample of interest; calculating the similarity between the MHL value of the DNA methylation haplotype block of the sample of interest DNA and the MHL value of a DNA methylation haplotype region of a respective classification label, and/or the similarity between the copy number variation data of the sample of interest DNA and the DNA copy number variation data of a respective classification label; and determining a classification for the DNA in the sample of interest by using a classifier model and based on the similarity. The present invention provides new means with good specificity and sensitivity for detection of tumors in the urogenital system.

公开(公告)号：US11633397B2

公开(公告)日：2023-04-25

申请号：US16363981

申请日：2019-03-25

申请人： Richard G. Pestell

发明人： Richard G. Pestell

IPC分类号： A61K31/506 ,  G01N33/50 ,  A61K31/46 ,  G01N33/574 ,  A61K31/4184 ,  A61K31/4375 ,  C12Q1/6886

摘要： This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

公开(公告)号：US20230124836A1

公开(公告)日：2023-04-20

申请号：US17822484

申请日：2022-08-26

申请人： BIOSCIENCE SERVICES S.R.L.

发明人： Giuseppe Mucci

IPC分类号： C12Q1/6886 ,  G16B20/20 ,  G16B20/50

摘要： A system is shown that performs a method that searches for and identifies a genetic condition prodromal of the onset of solid tumors in a healthy subject. The method includes an evaluation cycle of a genetic stability or instability condition and at least one repetition of the evaluation cycle. The repetition cycles are performed periodically on the subject, with the frequency depending on the result of the previous cycle. Each cycle includes taking a sample, verifying the presence of mutations, verifying the frequency of mutations, recording the mutations, defining or updating a genetic instability index of the subject, evaluating, in each repetition cycle, the subject's entry into a prodromal genetic condition upon the onset of one or more solid tumors or groups of solid tumors on the basis of a threshold value (ITS,IGS) of the genetic instability index (IT,IG), defined for each single gene or group of genes, being exceeded.